Drugs / [177Lu]Lu-XT117
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06197139 | Jan 2024 → Dec 2025 overdue | neoplasm | Xinlu Wang | Recruiting | No outcome recorded |
| Phase 1 | NCT06211647 | Jan 2024 → Dec 2025 overdue | cancer or benign tumor | Ruimin Wang | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | [177Lu]Lu-XT117 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06211647 ↗ |
| Modality | Other / unclassified | “a novel fibroblast activation protein (FAP)-targeted radioligand” PMID 41087606 ↗ Oct 2025 |